CORT — Corcept Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.68bn
- $3.31bn
- $761.41m
Annual cashflow statement for Corcept Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | C2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 113 | 101 | 106 | 141 | 99.7 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 50 | 46 | 41.1 | 51 | 80.1 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.057 | 6.02 | 8.22 | 45.5 | -1.41 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | 168 | 120 | 127 | 198 | 142 |
| Capital Expenditures | -0.469 | -0.413 | -0.139 | -2.17 | -0.211 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 137 | -114 | 91 | -175 | 70 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 136 | -114 | 90.9 | -178 | 69.8 |
| Financing Cash Flow Items | -22.8 | -21.7 | -9.11 | -16.8 | -63.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | -303 | -17.3 | -149 | -28.3 | -220 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.43 | -11.3 | 69.2 | -7.89 | -7.17 |